Clinical Trials Arena on MSN3mon
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpointThe company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback